drugset / Trial / NCT04560881
Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)
Phase 3
Completed
3000 enrolled
Laboratorio Elea Phoenix S.A.
Beijing Institute of Biological Products Co Ltd. · collabChina National Biotec Group Company Limited · collabFundación Huésped · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
This is a randomized, double blind, placebo parallel-controlled phase III clinical trial to evaluate the efficacy, immunogenicity and safety of the inactivated SARS-CoV-2 Vaccine (Vero cell) in Argentine healthy population aged between 18 and 85 years old.
Timeline
- Start
- 2020-09-16
- Primary completion
- 2021-12-13
- Completion
- 2021-12-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inactivated SARS-CoV-2 vaccine (Vero cell) | Vaccine | — | Intramuscular |